共 50 条
Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect:: a retrospective analysis
被引:24
|作者:
Meinardi, JR
Middeldorp, S
de Kam, PJ
Koopman, AMW
van Pampus, ECM
Hamulyák, K
Prins, MH
Büller, HR
van der Meer, J
机构:
[1] Univ Hosp, Div Haemostasis Thrombosis & Rheol, NL-9713 GZ Groningen, Netherlands
[2] Univ Hosp, Trial Coordinat Ctr, Groningen, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Ctr Haemostasis Thrombosis Atherosclerosis & Infl, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Hosp, Dept Haematol, Maastricht, Netherlands
关键词:
thromboembolism;
blood coagulation disorders;
activated protein C resistance;
factor V;
D O I:
10.1097/00001721-200112000-00014
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Factor V Leiden is the most common genetic defect associated with venous thromboembolism. Its clinical expression is limited and shows a wide intrafamilial and interfamilial variation, which might be explained by the influence of other genetic risk factors. We retrospectively studied 226 patients with factor V Leiden and documented venous thromboembolism (probands) and 400 first-degree carrier relatives to assess the contribution of concomitant genetic risk factors to the occurrence of venous thromboembolism. The prothrombin G20210A mutation was found in 8.3%, homozygosity of factor V Leiden in 7.2%, and inherited deficiencies of antithrombin, protein C or protein S in 4.7% of symptomatic carriers (probands and relatives), as compared with 6.0, 3.4 and 0.9% of asymptomatic carriers, respectively. The total follow-up time in relatives was 11049 years. Prevalences of venous thromboembolism were 10.8% in single heterozygous factor V Leiden carrier relatives, 16.0% in double-heterozygotes for factor V Leiden and the prothrombin mutation, 36.8% in homozygotes for factor V Leiden, and 40.0% in double-heterozygotes for factor V Leiden and an inherited deficiency of protein C or protein S. Annual incidences in these groups were 0.39, 0.57, 1.41, and 4.76%, respectively. Multivariate analysis showed a small, non-significant additional effect of the prothrombin mutation on the risk of venous thromboembolism in heterozygotes for factor V Leiden [adjusted hazard ratio, 1.3; 95% confidence interval (CI), 0.5-3.8]. This effect was more pronounced for homozygosity of factor V Leiden (adjusted hazard ratio, 3.9; 95% CI, 1.7-9.0) and inherited protein C or protein S deficiencies (adjusted hazard ratio, 17.5; 95% CI, 3.8-81.2). Our data provide evidence of clustering of the evaluated genetic thrombophilic defects in symptomatic factor V Leiden carriers and support the assumption that the clinical expression of factor V Leiden depends on clustering in a part of carriers. Blood Coagul Fibrinolysis 12:713-720 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:713 / 720
页数:8
相关论文